Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.
All Specialties March 6th 2024
Practical Neurology
The TASTE-SL trial presents compelling evidence that Sanbexin, a sublingual combination of edaravone and dexborneol, offers a significant improvement in recovery for acute ischemic stroke patients, marking a notable advancement in neuroprotective treatment strategies.
Neurology March 5th 2024
OBR Oncology
The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.
Hematology/Oncology February 20th 2024
Cancer Therapy Advisor
In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.
Oncology, Medical February 5th 2024
In a major stride for cervical cancer treatment, the FDA-approved pembrolizumab in combination with CRT demonstrates significant improvement in progression-free survival for FIGO 2014 stage III-IVA patients, marking a pivotal change in therapeutic approaches.
Hematology/Oncology January 22nd 2024
The New England Journal of Medicine
The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.
Oncology, Medical January 2nd 2024